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PARDIOVASCULAR GENOMIC MEDICINE
ene Expression Analysis of Cardiovascular Diseases
ovel Insights Into Biology and Clinical Applications
avid Seo, MD, Geoffrey S. Ginsburg, MD, PHD, Pascal J. Goldschmidt-Clermont, MD
urham, North Carolina
Although the contribution of genetics to complex cardiovascular diseases such as atheroscle-
rosis has been accepted for quite some time, full and detailed knowledge of the individual
causative genes has been elusive. With the advent of genomic technologies and methods, the
necessary tools are now available to begin pinpointing the genes that contribute to disease
susceptibility and progression. One approach being applied extensively in candidate gene discovery
is gene expression analysis of human and animal tissues using microarrays. The genes identified
by these genomic studies provide valuable insight into disease biology and represent the initial
steps toward the development of diagnostic tests and therapeutic strategies that will
substantially improve human health. This paper highlights the progress that has been made
in using gene expression analysis cardiovascular genomic research and the potential for
applying these findings in clinical medicine. (J Am Coll Cardiol 2006;48:227–35) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.070by the American College of Cardiology Foundation
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rn April 14, 2003, the International Human Genome
equencing Consortium, led in the United States by the
ational Human Genome Research Institute (NHGRI) of
he National Institutes of Health and the Department of
nergy, announced completion of the Human Genome
roject (1). This announcement heralded the start of a new
ra in medical science in which genomic data will markedly
mprove our ability to diagnose and treat heart disease,
ancer, and a myriad of chronic diseases. Understanding the
elevance of an individual’s genomic profile or “molecular
ngerprint” in a disease context now might help us to gain
aluable insight into disease mechanisms and could be the
oundation for tailoring health care to the individual patient
n the basis of their predicted disease course and response to
herapies. The opportunity also now exists to replace diag-
ostic tests that are currently invasive in nature with
enomic tests that can be performed without detectable risk
r significant stress to the patients (2,3). The objective of
his article is to provide an overview of the state of genomic
esearch in cardiovascular medicine, specifically with regard
o the use of microarray technology and functional
enomics.
ACKGROUND
ith common cardiovascular diseases such as atherosclero-
is, atrial fibrillation, and heart failure affecting millions of
mericans and costing our health care system billions of
ollars, the manner in which clinicians diagnose and treat
isease must change (3–6). Considering disease progression
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edical Center, Durham, North Carolina. Joshua Hare, MD, served as guest editor
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Manuscript received October 19, 2005; revised manuscript received January 27,
006, accepted February 8, 2006.s a series of distinct “states,” the goal for clinicians is to
tabilize patients within a disease state and reduce the
robability that they will progress to the next, often worse
tate. Moreover, many of the current therapies for a given
tate have been derived from large prospective studies such
s the PRISM (Platelet Receptor Inhibition in Ischemic
yndrome Management) and the CURE (Clopidogrel in
nstable Angina to Prevent Recurrent Events) trials. The
ubjects in the treatment and control groups in these studies
re, through a process of randomization, ostensibly consid-
red to be identical. And although there might be a
tatistically significant overall treatment effect, it is impos-
ible to know whether a treatment regimen will be effective
or a specific individual. As a case in point, the state-of-
he-art treatment for acute coronary syndromes uses a
ocktail of 5 to 8 drugs for every patient. At present, we
annot identify which medication or combination of med-
cations will provide the optimal benefit-to-risk ratio for the
ndividual patient. Thus, 2 patients in the same disease state
hat are otherwise identical with respect to measurable
ariables, such as demographics, laboratory values, and
omorbidities, might have marked differences in clinical
ourse with respect to tempo and intensity of disease
evelopment and therapeutic response (7–9).
The greatest limitation in optimizing therapeutic strate-
ies for the individual patient is an incomplete understand-
ng of disease biology and inability to differentiate individ-
als according to their relative disease risk. The inherent
enetic makeup of individuals is likely to play a large role in
etermining clinical course by modulating response to risk
actors such as smoking, cholesterol, and obesity. For
xample, the intrinsic capacity for arterial and cardiac repair
ight be genetically determined and play a dominant role
elative to the eventual impact of cardiovascular injuries. By
dentifying the genes and gene variants that determine
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Gene Expression Analysis of Cardiovascular Diseases July 18, 2006:227–35ndividual disease susceptibility, we might be able to design
ealth care plans that not only identify patients in the
reclinical stages of disease but also allow for individualized
herapies that are most efficacious and least likely to cause
ide effects (3,7,8,10).
DENTIFYING CANDIDATE
ENES THROUGH RNA PROFILING
n the pre-genomic era, the opportunity to identify a
elevant set of causative genes for multigenic diseases such as
therosclerosis and cardiomyopathies was limited. Tradi-
ional genetic approaches were designed to find single loci
r genes with the power to cause Mendelian cardiovascular
isorders such as the prototypical familial hypercholesterol-
mia. These types of disorders can result from a single base
hange in the deoxyribonucleic acid (DNA) that leads to
ignificant changes in protein abundance or function. How-
ver, in common “garden-variety” disorders, such as athero-
clerosis, the artery-specific inflammatory process likely
esults from multiple gene variants that interact to modulate
n individual’s response to clinical risk factors such as
moking, serum lipids, and hypertension. These gene vari-
nts usually take the form of single base changes in the
NA or single nucleotide polymorphisms (SNPs) that
ause only a modest to moderate change in the resulting
ranslated protein (either concentration, function, or a
ombination of both). However, it is the concurrent pres-
nce of a number of SNPs within a specific mix of risk
actors that determines an individual’s susceptibility to
isease development and progression (11–13). The small
ontribution of each SNP to the disease makes them
ifficult to detect by traditional genetic association studies.
The obvious critical challenge is to identify the genes that
ollectively contribute to multigenic disorders such as ath-
rosclerosis and cardiomyopathies. With the advent of
road-based genomic technologies, one approach that has
merged as a real opportunity is to perform gene expression
nalysis of disease-relevant tissues to look for changes in the
bundance of transcribed genes or messenger ribonucleic
cids (mRNAs) that correlate with a particular disease state,
linical outcome, or therapeutic response. Although DNA
Abbreviations and Acronyms
CARGO  Cardiac Allograft Rejection Gene Expression
Observational study
DNA  deoxyribonucleic acid
ICM  ischemic cardiomyopathy
LVAD  left ventricular assist device
mRNA  messenger ribonucleic acid
NF  nonfailing (myocardial samples)
NICM  nonischemic cardiomyopathy
PMBC  peripheral blood mononuclear cell
QTL  quantitative trait locus
SNP  single nucleotide polymorphismefines a person’s inherent genetic make up, it is the active
F
oranscription of the DNA to RNA that integrates an
ndividual’s dynamic interaction with the environment.
herefore, genomic studies provide us with the opportunity
o identify genes whose relative RNA abundance changes
nder differing biological conditions, with the premise that
uch altered expression response highlights culprits for the
isease process. There are numerous ways to measure RNA
bundance, including Northern blotting and multiplex real
ime polymerase chain reaction. However, these techniques
an quantitate expression levels on the order of 10 to 50
enes at a time.
More recently, genomic technologies such as DNA mi-
roarrays provide us with an opportunity to assay thousands
f genes simultaneously, giving us an unprecedented oppor-
unity to survey the genomic contribution to cardiovascular
iseases (14–16). Microarrays refer to solid substrates of
lass, plastic, or silicon that contain thousands of micro-
copic printed spots of DNA (Fig. 1). Each of the DNA
pots consists of hundreds to thousands of identical short
ieces of DNA, also called probes, that have been apposed
o the solid material. Each probe has a unique sequence of
ucleotide base pairs that is complementary and unique to a
ingle gene. Most microarray experiments today use “gene
hips” on which the entire complement of the human
enome is represented. In a typical microarray experiment,
NA is extracted from a tissue or sample of interest. The
RNA, which is the fraction of the RNA population that
epresents the transcribed genes, is amplified, and fluores-
ent tags are attached to each molecule. The entire pool is
hen incubated with the microarray, and the tagged mRNA
olecules hybridize to the probes containing the specific
omplementary sequence via base pairing. Complementary
RNAs bind to probes on the array during hybridization.
he microarray is then placed in a scanner where a laser is
irected onto each spot, causing the tags to fluoresce. The
esulting fluorescent intensity is proportional to the number
f tagged RNAs that have hybridized to the probes in each
pot, and therefore the measured intensity represents the
ctivity or expression level of that gene. Consequently, a
enomic profile can be generated for a particular tissue at
ny stage of health or disease.
The utility of these gene signatures, generally speaking, is
wo-fold: 1) as an initial step in identifying disease-
ssociated genes, or “candidate genes;” and 2) as a diseaseigure 1. Schematic of a microarray assay. cDNA; complementary de-
xyribonucleic acid; cRNA  complementary ribonucleic acid.
b
g
t
a
m
S
f
p
s
a
f
g
a
a
t
a
c
t
c
p
o
C
T
T
t
t
l
e
v
h
t
A
s
l
f
c
c
d
p
d
a
p
t
s
a
i
r
s
p
t
p
a
m
c
i
m
b
u
l
t
a
o
e
i
a
c
C
A
b
c
a
l
b
p
a
e
t
a
R
m
a
o
fi
a
g
e
t
o
c
v
i
s
b
l
g
f
i
l
e
t
m
g
s
n
229JACC Vol. 48, No. 2, 2006 Seo et al.
July 18, 2006:227–35 Gene Expression Analysis of Cardiovascular Diseasesiomarker. In the first instance, the genes that comprise the
enomic signature are by definition disease-associated and
hus are the candidates in which to look for SNPs that are
ssociated with disease susceptibility or a particular treat-
ent outcome. By identifying a potential panel of disease
NPs, we could then screen a patient’s DNA via a blood test
or the presence of these gene variants to aid in diagnosis or
lanning treatments. Certainly these candidate genes might
ubstantially improve our understanding of disease biology
nd subsequently lead to identification of potential targets
or new treatment strategies (17). The other potential use of
enomic information is to use the gene signatures directly as
disease biomarker. Gene expression data in the appropri-
te setting is an extraordinarily detailed patient phenotype
hat could be used to accurately stratify patient populations
s to their disease risk or response to therapies. In both
ases, genomic data represent a means to distinguish be-
ween patients who are otherwise identical by traditional
linical variables (14–16). Although this is still a work in
rogress in cardiovascular medicine, we can look to the field
f oncology to see where the future lies.
ANCER GENOMICS AS A
EMPLATE FOR CARDIOVASCULAR MEDICINE
he clinical use of genomics has advanced most rapidly in
he area of oncology, owing in part to the inherent advan-
age of being able to directly assay the tumors. The cancer
iterature provides us with some guidance on how gene
xpression data might be applied in the context of cardio-
ascular medicine. A predominant role for cancer genomics
as been to risk-stratify patients that have been classified by
raditional clinical factors with greater granularity (18).
fter the initial diagnosis and clinical staging, gene expres-
ion profiling of the tumor has been used to predict
ong-term disease recurrence and survival as well as possibly
or planning treatment regimens (19–21). In the most
oncrete example, patients who are at high risk for breast
ancer recurrence can be identified even at early stages of the
isease. Two tests are commercially available in the U.S. for
atients with early invasive breast cancer. Both tests are
esigned to complement the diagnostic armamentarium
vailable to clinicians to select the most appropriate thera-
eutic strategy for patients with early-stage breast cancer. In
his population, patients traditionally undergo surgical re-
ection followed by radiation treatment and hormonal
djuvant therapy. These new genomic assays seek to identify
ndividuals that are at significantly higher risk for recur-
ence, potentially warranting more aggressive treatment
trategies with chemotherapy in spite of a rather good
rognosis as indicated by traditional risk profiling (18). It is
he integration of the molecular characteristics from the
atients’ tumors with clinical and demographic data that
llows for this additional granularity in clinical decision-
aking. aGenomic research has progressed more slowly in the
ardiovascular field, owing to the inability to access enough
nformative tissues. Perhaps this has been the reason that
uch more effort has gone into looking for disease SNPs,
ecause these can be both studied and tested through the
se of blood (DNA) samples. Still, within the past 3 years,
andmark studies using human aortic, atrial, and ventricular
issues have improved our understanding of disease biology
nd are being translated to applications that might improve
ur ability to make clinical decisions. It has also become
vident that blood cells can also provide usable genomic
nformation for cardiovascular conditions. We now turn our
ttention to recent significant research in the area of
ardiovascular genomics.
ARDIOVASCULAR GENOMICS
therosclerosis. Given the extraordinarily heavy health
urden of atherosclerosis and its thromboembolic compli-
ations, this condition has been one of the first foci for
pplied genomic technologies. The availability (or relative
ack) of appropriate human target tissues has until recently
een a critical limiting factor. In a recent study, investigators
erformed gene expression analysis exclusively on human
ortic tissues to identify genes that are predictive for the
xtent of atherosclerotic burden in the aorta (22). The
issues were collected at the time of organ harvest from heart
nd lung donors and preserved to maintain premortem
NA integrity. The inherent symmetry of disease develop-
ent about the longitudinal midline of the thoracic aorta
llowed a quantitative analysis of atherosclerosis on one-half
f the specimen and performance of gene expression pro-
ling on the other half. The seemingly palindromic char-
cter of the disease mosaic allowed for direct association
ene expression profiles to disease burden phenotype. Gene
xpression data were then used to develop predictive models
hat accurately classified unknown aortas as having minimal
r severe disease with over 90% accuracy. The predictive
apability of these genes implies potential biological rele-
ance. The genes that provided this predictive capability
ncluded not only many previously associated with athero-
clerosis as well as an entirely novel set of genes that never
efore had been linked to cardiovascular disorders but also a
arge number of genes whose role in atherosclerosis had
one unrecognized.
Given the challenges in obtaining human arterial tissues
or studies of atherosclerosis, animal models have been
nvaluable as tools for determining the mechanisms under-
ying disease progression and the influence of diet and other
nvironmental factors on its expresssion. The apolipopro-
ein E knock out (apoE/) is a well-established disease
odel of atherosclerosis that has been used for years with
reat relevance to human disease. This model allows the
tudy of atherosclerotic inflammation while controlling for a
umber of important clinical variables such as age, gender,
nd diet on a genetically homogenous background. In a
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Gene Expression Analysis of Cardiovascular Diseases July 18, 2006:227–35ecent study, gene expression analyses using aortas from
poE/ mice of different ages and diets defined a genomic
ignature for disease burden that could differentiate between
he different mouse atherosclerotic disease states (23). This
enomic model was then tested in human disease by profiling
enes in mRNA from atherectomy samples extracted from
therosclerotic lesions and from in-stent restenotic lesions. The
ndings were that the mouse genomic signature could clearly
ifferentiate between atherosclerotic and restenotic lesions with
high degree of accuracy, thus validating in humans the
enomic predictor discovered in the mouse. This is impor-
ant, because it suggests that genomic data derived across
pecies might be applicable to human disorders. A similar
ene expression analysis of mouse atherosclerosis models
howed similar findings with regard to genomic signatures
ndicative of different disease states and that genomic
ignatures from mouse tissues were homologous to those
een in human tissues (24). This study also went further to
emonstrate the presence of a molecular repair signal in the
ouse aortas that implicates the role of bone marrow-
erived progenitor cells in the balance between vascular
amage and restoration. This is one of the first instances in
hich chronic disease progression has been directly linked
o changes in the body’s ability to repair itself. Therefore,
his study not only implicated a series of gene programs as
isease progresses but also demonstrated that gene expres-
ion analysis can implicate specific disease mechanisms.
The results from these studies currently have no direct
iagnostic utility, because they rely on the availability of
isease tissues. However, the information contained in the
ene expression signature (i.e., the genes making up the
ene expression pattern) that differentiates one disease state
rom another serves as the basis for “candidate gene”
dentification for use in genetic association studies. Al-
hough whole genome scanning and association studies will
ikely supersede the candidate gene approach, candidate
enes identified in a gene expression signature can also be
sed to facilitate whole genome scans by prioritizing targets
ithin chromosomal regions. In contrast to the traditional
ethod of identifying candidates through their established
ole in the biology of disease, gene expression represents a
ovel and nonbiased methodology. Thus genes identified by
enomic studies can be used as the basis for genetic
ssociation studies, or these genes might identify new
iology relevant to the disease process. A key challenge that
emains is to identify which gene or genes are causative and
unctionally relevant.
The most clinically relevant application of genomic tech-
ologies in cardiovascular medicine would be “point-of-
are” assays for diagnostics with a simple blood-based test,
nd there is now evidence to suggest that this might be a
eal possibility. The peripheral blood mononuclear cells
PMBCs) play a critical role in inflammatory pathways
eading to atherosclerosis and constitute a major cellular
omponent of atherosclerotic lesions and their repair.
herefore, gene expression profiling of PBMCs could Iotentially yield a diagnostic signature for atherosclerosis.
ne of the earliest studies was performed in a small group
f patients with and without significant coronary artery
isease (four cases and three control subjects) (25). With
NA extracted from the PBMCs from these patients,
nvestigators evaluated the relative abundance of over
0,000 transcripts. They found over 100 genes that were
ignificantly up-regulated or down-regulated in the patients
ith coronary disease compared with the normal control
ubjects. Although this was a small study, it points to the
easibility of using gene expression profiling of blood to
etect coronary heart disease. Another recent study also
rovides additional evidence that blood gene expression
rofiling might have utility in the detection of atheroscle-
osis (26). Investigators performed gene expression analysis
f PBMCs to find genes that were differentially expressed in
atients with carotid atherosclerosis. Gene expression sig-
atures from patients with severe carotid atherosclerosis
ecessitating surgical intervention were compared with a
ontrol cohort without measurable disease. The investiga-
ors found a number of regulatory genes and transcription
actors, including Finkel-Biskis-Jinkins osteosarcoma proto-
ncogene, dual specificity phosphatase-1, and nuclear factor of
appa light polypeptide gene enhancer in B-cells inhibitor-
lpha, that were significantly altered in patients with severe
arotid disease. Given the sample sizes used, this study was
eant to be an exploratory analysis that identified differen-
ially expressed genes for improving biological insight into
therosclerosis with PBMCs as reporter cells. It has not
een validated for use as a diagnostic or prognostic tool.
owever, it provides proof on concept that blood-based
ene expression data seem to be informative for an individ-
al’s overall inflammatory state, with possibly more specific
nformation relevant to carotid atherosclerosis. The identi-
ed genes might represent genes whose variants might
ontribute to pathologically enhanced inflammatory re-
ponses to endothelial damage from high serum cholesterol
r hypertension. This is one of the first studies to show that
ssays of PBMCs have potential to be informative in a
iagnostic context for presence or absence of atherosclerosis
n humans.
One could envision that genomic profiling of PBMCs
ould serve as an adjunctive test to noninvasive functional
tudies to improve sensitivity and specificity for the presence
r absence and severity of disease. An important consider-
tion here is whether carotid atherosclerosis will be associ-
ted with gene expression profiles that are distinct from
hose associated with coronary, aortic, or lower extremity
ascular disease.
ardiac transplant. Significant progress has been made in
he application of genomic information to predict the risk of
cute rejection in patients who have undergone cardiac
ransplantation. In one study, researchers profiled PBMCs
n a cohort of cardiac transplant patients and found a pattern
f gene expression statistically associated with rejection (27).
n this study, longitudinal clinical data and blood samples
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July 18, 2006:227–35 Gene Expression Analysis of Cardiovascular Diseasesere collected at the time of surveillance right heart biop-
ies. Periodic right heart biopsies are standard of care for
ssessing signs of acute rejection, often before its clinical
anifestations. Analysis of the gene expression data from
he PBMCs collected from transplant patients showed
ifferentially expressed genes that predicted the develop-
ent of acute rejection as defined by histological diagnosis
nd blood serum assays. In addition, in patients that
xperienced rejection, the majority of discriminatory genes
eturned to baseline levels of expression after treatment from
he immune rejection episode. These results not only
upport the utility of gene expression for diagnosis but also
he potential use of genomic data to measure response to
reatment.
With a similar study design, another research group also
ound genes in PBMCs that are predictive for acute rejec-
ion in cardiac transplant patients (28,29). These findings
ave led to the development of a commercially available,
lood-based test for detection of acute cardiac rejection.
he investigation examined data from 600 transplant recip-
ents in the multi-institutional CARGO (Cardiac Allograft
ejection Gene Expression Observational) study. The
ARGO study investigators collected longitudinal clinical
ata and blood samples at the time of surveillance right
eart biopsies. Analysis of the gene expression data from the
BMCs identified a core group of genes that were differ-
ntially expressed in patients at various stages of acute
ejection. With this information, a blood-based test was
eveloped that assigns risk for developing rejection within
he next 3 months with a negative predictive value of over
0% (29,30). Therefore, purely on the basis of gene expres-
ion data from peripheral blood, this test might allow
atients to forego the risk, albeit minimal, of surveillance
ight heart biopsies if the results are negative. These studies
ave also shown that the genomic data might be informative
s to the level of immunosuppression required for individual
atients, particularly as to whether they were receiving an
ffective dose of corticosteroids independent of the actual
ose (31). For example, a patient receiving 40 mg of
rednisone might have a gene expression profile that is more
ypical of a patient receiving an 80-mg dose, indicating that
he gene expression profile might be a more accurate
harmacodynamic biomarker for dose finding than tradi-
ional methods. Although further data are needed to sub-
tantiate this finding, it represents an opportunity for the
arly application of pharmacogenomics to assist in drug
itration.
One issue with these types of studies will be the sensi-
ivity of the test for predicting clinical outcomes. The ability
o thoroughly assess an accurate and reproducible phenotype
s an absolute necessity for the use of gene expression to
rive decision-making. In the CARGO study, the pheno-
ype associated with gene expression was the histological
rade of rejection determined by a panel of clinicians. If
here is substantial variability in the grading of rejection in
he myocardial samples, this will affect the consequent teliability of the assay for predicting rejection. As more
pplications of genomics to clinical practice are developed,
he accuracy of the measure phenotype will be crucial. In any
vent, the gene expression-based assay for transplant rejec-
ion represents the first substantial and clinically relevant
pplication of genomics in the field of cardiovascular medicine.
lectrophysiology—atrial fibrillation. The field of elec-
rophysiology provides a tremendous opportunity for
enomic data to guide clinical decision-making. New
evice-based therapeutic strategies have been developed that
re of unmatched benefit to the patients who need them
ost but also come with substantial side effects, particularly
f applied to patients who need them least (32–34). Fur-
hermore, it has become increasingly evident that arrhyth-
ias result from the combined effect of myocardial degen-
ration, aging, and to a smaller extent, “channelopathies,” or
enetic variations in ion channels (35–37). Each individual
ffect is influenced by genetic factors, which by themselves
o not lead to abnormal rhythms. However, when the
enetic factors are combined and interact, arrhythmias
ight develop. In this context, the first application of
icroarray technology has been to improve our understand-
ng of the biology of arrhythmias, in particular atrial
brillation. Two groups have recently published results of
unctional genomic studies using human tissues. Both stud-
es used the right atrial appendages obtained at the time of
oronary artery bypass surgery or valve repair surgery for
heir gene expression profiling assays. One study evaluated
,800 known genes with DNA microarrays and found 50
enes that were differentially expressed in the atrial fibrilla-
ion samples relative to the control samples in normal sinus
hythm (38). Within the predictive gene expression signa-
ure was a preponderance of genes related to reactive oxygen
pecies and enzymes that modulate response to oxidative
tress. This led to speculation that oxidative damage, per-
aps through the inflammatory pathways, could be one of
he initiators of atrial fibrillation as well as a potentiator of
he condition. This study used a relatively limited gene set
y current standards; it was one of the first broad, nonbiased
nvestigations of molecular changes in humans with atrial
brillation. Another similar investigation also used atrial
issue samples taken at the time of cardiac surgery to find
enes associated with the presence of chronic atrial fibrilla-
ion but assayed for a larger set of over 12,000 genes (39,40).
n patients with atrial fibrillation, compared with individu-
ls in normal sinus rhythm, the investigators found differ-
ntial expression in genes related to remodeling, contractile
roteins, and ion channel changes. In addition, changes in
xpression of genes related to metabolism were observed
hat might be indicative of higher energy needs in the
brillation state. Each of these studies sought to improve
iological insights into atrial fibrillation. As in the study of
therosclerosis, neither was meant to yield data that could
e used directly in diagnostics. The prioritized genes can
elp to suggest possible mechanisms that might contribute
o development of atrial fibrillation. Obviously, the ability to
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Gene Expression Analysis of Cardiovascular Diseases July 18, 2006:227–35tudy readily accessible tissues would be ideal for clinical
enomics, but at this point it is difficult to say whether this
ill be possible. What is more likely will be the construction
f clinical tests that assess for genetic polymorphisms that
ight indicate susceptibility for developing arrhythmias or
esponse to pharmacologic therapies.
ypertension. Although hypertension is extraordinarily
mportant in cardiovascular medicine, genomic studies of
umans have been difficult, given the lack of accessible
issues. Much of what we know about the molecular
echanisms contributing to hypertension has been devel-
ped with animal models. In the search for hypertension
andidate genes with animal models, one technique that has
een used extensively is the identification of quantitative
rait loci (QTLs). A QTL is a portion of a chromosome that
s highly associated with a trait, such as high blood pressure.
ne problem has been that a QTL might consist of
undreds of genes. The emergence of microarray technol-
gies has provided a method for prioritizing the genes
ithin these QTLs that might warrant further study. With
strategy known as “genomic convergence,” some investi-
ations have combined gene lists derived from QTL map-
ing and gene expression analysis of disease-relevant tissues
o find the overlapping members (41,42). The genes iden-
ified at the interface between two disparate approaches
ight therefore represent particularly intriguing candidate
enes. One study that illustrates this approach used the
abra rat hypertension model of salt susceptibility. Indepen-
ent QTL analysis was performed, showing two loci on
hromosome 1 of the rat genome that was highly associated
ith the hypertensive phenotype (42). One locus spanned
3.1 centimorgans and has been shown to contain 2,933
nown genes, whereas the other spanned 18 centimorgans
ith 1,102 genes. Gene expression profiles were generated
rom the rat kidneys, because it was felt that this organ was
ntimately involved in sodium balance. The researchers
ound seven genes that overlapped between the QTL and
ene expression analyses. Although this is an animal study,
t represents a powerful approach for studying human
isease biology when informative tissues are not readily
vailable. The polymorphisms from the genes identified by
his study can be used in human genetic association studies.
eart failure. Heart failure is the fastest-growing cardio-
ascular disease. Recently, new device therapies such as
iventricular resynchronization and automatic defibrillators
ave expanded the armamentarium of strategies to treat
atients with heart failure (43–46). Patients with heart
ailure also receive a complex medication regimen and have
heterogenous clinical course, just as with other common
ardiovascular diseases. As such, genomic analyses might
lay a substantial role in improving diagnostics and health
are planning. The availability of human tissues obtained at
he time of transplant or placement of left ventricular assist
evices (LVADs) has facilitated the use of microarray
nalyses to study cardiomyopathies. The first groups of tecent genomic studies have sought to differentiate between
schemic and nonischemic cardiomyopathies.
A recent study examined a number of myocardial samples
o look for gene expression differences between end stage
schemic and nonischemic subtypes (47). They also at-
empted to develop the genomic profile for more interme-
iate clinical phenotypes by studying tissues obtained at the
ime of diagnostic biopsy and LVAD placement. This larger
tudy examined nearly 50 myocardial samples, from two
ifferent institutions, obtained at the time of transplantation/
xplantation, LVAD placement, or biopsy. Furthermore, the
amples represented a range of clinical disease stages, from new
iagnosis to end-stage disease requiring transplant. The re-
earchers demonstrated the ability to differentiate between
atients with ischemic and nonischemic cardiomyopathies
mong the end-stage patients with remarkable 100% accu-
acy. However, predictive accuracy for classifying samples as
schemic or nonischemic dropped substantially in the
VAD and newly diagnosed cohorts. Instructively, age,
ender, and hemodynamic differences in the patient cohorts
id not add power to any of the predictive models used in
he study. Overall, this study demonstrates the potential
linical applications for classifying patients into cardiomy-
pathy subtypes by using genomic phenotypes. The genes
hat differentiate between the groups in this study might
rovide clues as to how treatment regimens could be tailored
or specific subtypes. Finally, although not described spe-
ifically, the genes that differentiate between the different
ardiomyopathy subtypes over time aid in targeting of
herapies depending upon the stage of the natural history of
he disease process as well as tracking response to therapies.
This same group of investigators also performed addi-
ional analyses with the same sample cohort and identified
ifferentially expressed genes without assessing their predic-
ive capability (48). The reason for the additional analyses
as the authors’ assertion that the candidate genes arising
rom the predictive models, although instructive, were not
ruly indicative of disease biology. Rather, they represent a
table expression profile for a particular disease setting.
lthough this is still an unresolved issue, they nevertheless
rovided a more detailed analysis of the gene expression
ifferences between patients with ischemic and nonischemic
ardiomyopathies. In 21 nonischemic cardiomyopathy
NICM) samples, 10 ischemic cardiomyopathy (ICM) sam-
les, and 6 nonfailing (NF) myocardial samples, 257 genes
ere found that were significantly differentially expressed in
ICM compared with NF hearts and 72 genes when
omparing ICM with NF hearts. There were 41 genes that
verlapped across these two comparisons and represented
iological processes relevant to cell growth and signal
ransduction. Genes unique to NICM were related to
etabolism, and those unique to ICM seemed to be related
o catalytic activity. Angiotensin-converting enzyme-2 was
p-regulated in NICM but not in ICM samples, pointing to
potentially different pharmacologic target in patients with
hese two entities. An important issue with genomic studies
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he comparison. In one sense, the diagnosis of nonischemic
r idiopathic dilated cardiomyopathy likely represents pa-
ients with a wide spectrum of unrelated conditions as well
s patients with a mix of both ischemic and nonischemic
eatures. In addition, such analyses performed thus far do
ot take into account the gene changes induced by treat-
ent regimens. Furthermore, comparisons between end
tage and normal tissues might yield results that are difficult
o interpret and potentially less useful clinically. However,
hese studies do illustrate that gene expression profiling of
yocardium or another tissue, such as blood, could be
tudied as a means to differentiate between clinical cardio-
yopathy entities, each of which might warrant slightly
ifferent pharmacologic regimens.
HALLENGES AND OPPORTUNITIES
here have been a number of substantial findings to date in
ardiovascular genomic research with the development of a
ommercially available diagnostic test. However there are
till some significant challenges if we are realize the full
otential of genomics in cardiovascular medicine. Among
hese hurdles are issues surrounding the use of larger
umbers of appropriate samples, validation of results, and
ocietal and ethical concerns.
The issue of having enough appropriate samples in gene
xpression studies is a substantial one on many levels. On
ne level, many studies, including ones described here, have
sed small numbers of samples—perhaps a total of 20 to 40.
uch limits relate to both the expense of the assays as well
s the availability of sufficient sample numbers. Without
arger sample numbers, the validity of analyses will remain
ontroversial. Therefore, although the data from these
tudies are still useful for exploration and hypothesis gen-
ration, they require further substantiation before any clin-
cal application of the results. The intrinsic genetic and
ocioenvironmental heterogeneity within human popula-
ions dictate that larger sample sizes, perhaps on the order of
undreds of samples, could make the results more clinically
pplicable. This might also allow researchers to fine tune
heir genomic analyses to detect nuances in disease states or
linical outcomes. For example, it is likely that there are
istinct gene groups that determine atherosclerotic suscep-
ibility in men versus women as well as between racial and
thnic groups. Sample size limitations prevent us from being
ble to study these important subpopulations. In the U.S.,
ulti-institutional investigations such as the CARGO
tudy are good examples of how the pooling of cohorts
nable researchers to generate clinically applicable informa-
ion (3,49–54). Internationally, there are a number of efforts
nderway to develop repositories of biological materials on
massive scale that can be used for genomic, genetic,
etabolomic, and proteomic studies. One of the first
rojects of this kind was the North Health project of
weden (55), which has a biorepository of over 85,000 cnique individuals. Two recent national projects are the
nited Kingdom Biobank (56) and Biohealth Norway (57)
hat plan to collect genetic material and clinical information
n up to 500,000 individuals.
Discussion of performing gene expression experiments on
significantly larger scale brings up the issue of costs. Larger
amples sizes would allow for more robust results and larger,
ruly independent training and testing sets to test clinical
tility. Depending on the microarray platform being used,
he per-sample costs for materials (reagents, microarrays)
nd RNA processing (extract, label, hybridize) can range
rom $300 to $700. This does not account for the costs of
ccruing, collecting, and storing comprehensive, longitudi-
al clinical information. Certainly, development of core
acilities can help to defray these costs. Still, genomic
esearch will require a substantial budget when using sample
izes that are useful for developing clinically usable results.
here are a number of technical advancements that might
ramatically reduce costs, with the development of high
hroughput microarray platforms. But regarding this issue of
ample numbers, we must make sure that we are using the
ppropriate samples. For example, in the context of cardio-
yopathies, the samples easiest to obtain might come from
ndividuals with end-stage disease, already receiving a mul-
itude of medications. It might be difficult to decipher the
nformation derived in this situation and might limit the
pplicability of the resulting information.
Another challenge facing genomic research is the process
f moving beyond exploratory studies for candidate gene
iscovery toward improving understanding of disease biol-
gy. After robust statistical analysis, identified candidate
enes can be used for diagnostic testing in a clinical setting.
owever, an understanding of disease mechanisms is
eeded if we are to truly learn how to improve health care
trategies. Therefore, candidate genes must be assessed for
unctional relevance to patients and disease processes. In
articular, it will be important to determine whether expres-
ion changes in the prioritized genes are through a causative
ole or rather the result of the disease process itself. This is
ritical for furthering our understanding of disease biology
nd subsequently improving our health care strategies. Use
f knock out/in or transgenic animals will be vital to these
ypes of studies. In addition, considering the time, expense,
nd technical challenges of such animal confirmatory stud-
es, researchers will need to develop some more novel and
traightforward methods, perhaps through the use of small
olecules, aptamers, or small interfering RNAs (58–62).
Finally, aside from the scientific challenges, there are a
umber of public policy issues that must be addressed. A key
ssue will be to shift health care delivery to one of individ-
alized health assessment that emphasizes prevention and
rognosis as genetic and genomic information is translated
o clinical practice. This will require modification in patient
ducation as well as changes in medical education. Clear
mprovements in health outcomes and reductions in health
are costs will need to be demonstrated to justify new and
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s we move toward being able to predict disease suscepti-
ility and treatment outcomes, legislation will likely be
ecessary to protect medical privacy and prevent potential
arriers to insurance or employment (63,64).
Cardiovascular genomic research is still in its formative
tages with regard to the translation of results of studies to
linical applications. However, examination of other medi-
al fields demonstrates the potential of genomic medicine
nd where cardiovascular medicine will be, possibly within
he next 5 years (Table 1) (65–71). Microarrays are already
eing used in oncology, infectious disease, and pharmacol-
gy to help clinicians better risk-stratify patients as well as
redict therapeutic responses and guide clinical decision
aking. The availability of a genomic test to detect acute
ejection in cardiac transplant patients represents the first
oncrete example of how we will start to use gene expression
ata in the mainstream clinical enterprise. We have already
tarted to gain substantial new insights into common
ardiovascular diseases. It is likely that diagnostic tests using
enomic information will be available in the near term to
mprove prediction of acute coronary syndromes as well as
he potential for development of malignant arrhythmias.
lthough significant challenges remain, cardiovascular
enomic medicine promises to improve patient care and
ower health care costs and will change the way we practice
edicine.
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